Citadel Advisors
VRCA icon

Citadel Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Citadel Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-510
Closed -$3.57K – 15659
2024
Q4 		$3.57K Sell
510
-140
-22% -$1.54K ﹤0.01% 13987
2024
Q3 		$9.43K Buy
650
+20
+3% +$901 ﹤0.01% 13257
2024
Q2 		$45.9K Buy
+630
New +$48.4K ﹤0.01% 11856
2024
Q1 		– Sell
-340
Closed -$24.9K – 15500
2023
Q4 		$24.9K Sell
340
-670
-66% -$27.5K ﹤0.01% 12438
2023
Q3 		$39.2K Buy
1,010
+470
+87% +$23.9K ﹤0.01% 12015
2023
Q2 		$31.2K Sell
540
-140
-21% -$8.5K ﹤0.01% 12309
2023
Q1 		$44.2K Sell
680
-130
-16% -$7.86K ﹤0.01% 12323
2022
Q4 		$22.3K Sell
810
-2,290
-74% -$61.1K ﹤0.01% 13056
2022
Q3 		$91K Buy
3,100
+1,480
+91% +$50.7K ﹤0.01% 11170
2022
Q2 		$31K Buy
+1,620
New +$81.4K ﹤0.01% 12206
2021
Q4 		– Sell
-1,040
Closed -$130K – 14831
2021
Q3 		$130K Buy
+1,040
New +$117K ﹤0.01% 12551

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Citadel Advisors's VRCA Position: Q3 2025 in Review

Citadel Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 6,866 shares — an estimated $36.4K sold.

Citadel Advisors first reported a position in VRCA in Q1 2022 and held it in 10 quarters. The position peaked at $510K in Q2 2023. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Citadel Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 6,866 Verrica Pharmaceuticals shares in Q3 2025, an estimated $36.4K.
  • Citadel Advisors first reported a position in Verrica Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Citadel Advisors's Verrica Pharmaceuticals position peaked at $510K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.